Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model☆ | Zendy

Masaki Hamamoto | Zendy; Michiharu Suga | Zendy; Takeshi Nakatani | Zendy; Yūzō Takahashi | Zendy; Yukio Sato | Zendy; Shuji Inamori | Zendy; Toshikatsu Yagihara | Zendy; Soichiro Kitamura | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model☆

Author(s) -

Masaki Hamamoto,

Michiharu Suga,

Takeshi Nakatani,

Yūzō Takahashi,

Yukio Sato,

Shuji Inamori,

Toshikatsu Yagihara,

Soichiro Kitamura

Publication year - 2004

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2004.01.054

Subject(s) - rolipram , cardiopulmonary bypass , phosphodiesterase inhibitor , anesthesia , lung , medicine , phosphodiesterase , endocrinology , chemistry , enzyme , biochemistry

Cardiopulmonary bypass (CPB) induces systemic inflammatory response with neutrophil activation and subsequent lung dysfunction. Rolipram, a selective phosphodiesterase type 4 inhibitor, blocks the decrease in levels of cyclic adenosine monophosphate associated with neutrophil activation. Here, we tested the protective effect of rolipram on CPB-induced lung injury in the rat.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research